Silence Therapeutics Announces Positive Phase 2 PV Results; Phase 3 Planned

What Happened

• On August 10, 2026 Silence Therapeutics filed an 8-K and issued a press release reporting positive topline results from the Phase 2 SANRECO trial of divesiran (6 mg/kg subcutaneous). The 36-week randomized, double‑blind, placebo‑controlled portion met its primary and key secondary endpoints. The company hosted a conference call and webcast the same day; related press materials were furnished as exhibits to the 8-K.

Key Details

• Primary endpoint: 88% clinical responders with divesiran vs 19% with placebo (p<0.0001). Response = no phlebotomy and hematocrit (HCT) <45% during weeks 18–36.
• Dose groups: Q6W response 93.8%; Q12W response 81.3%.
• Phlebotomy rate (weeks 0–36): mean 0.2 per patient for divesiran vs 2.1 for placebo (p<0.0001).
• Additional outcomes: improvements in HCT control, iron markers (including ferritin), and MPN‑SAF total symptom score; safety profile consistent with prior trials—well tolerated, infrequent/self‑limiting injection‑site reactions, two investigator‑reported grade 1 anemia events.
• Next step: company expects to initiate a Phase 3 trial evaluating Q12W dosing vs placebo in the first half of 2027.

Why It Matters

• The clear efficacy signal (large responder gap and reduced phlebotomy) plus a consistent safety profile support advancing divesiran into Phase 3, which is a material development for Silence Therapeutics’ clinical-stage pipeline. Investors should note the company’s planned Phase 3 timing (H1 2027) and the filing’s forward‑looking statement caution about risks and uncertainties.